Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

John P. Leonard, an expert in lymphoma and other blood cancers, was named director of the Center for Blood Cancers and chief of the Division of Hematology and Medical Oncology in NYU Grossman School of Medicine’s Department of Medicine. The Division of Hematology and Medical Oncology is a major clinical arm of the Perlmutter Cancer Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Study findings expand donor pool for blood cancers

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.

July 03, 2025

Vol.51 No.26

Drugs & Targets

REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is no longer necessary to ensure that the benefits of these CAR T-cell immunotherapies outweigh their risks and to minimize the burden on the healthcare delivery system of complying with the REMS.

July 03, 2025

Vol.51 No.26

In Brief

Peter Voorhees named associate director of clinical research at Wake Forest

Peter Voorhees was promoted to associate director of clinical research and will oversee clinical research for Atrium Health Wake Forest Baptist Comprehensive Cancer Center, as well as all processes related to clinical protocol and data management and protocol review and monitoring system.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology.

June 06, 2025

Vol.51 No.22

By Jacquelyn Cobb

Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

YOU MAY BE INTERESTED IN

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

Study findings expand donor pool for blood cancers

REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated

Peter Voorhees named associate director of clinical research at Wake Forest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Renew today!

Subscriber content

Never miss an issue!

Login

Study shows that patients receiving CAR T-cell therapy have improved QOL six months post-treatment

YOU MAY BE INTERESTED IN

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

Study findings expand donor pool for blood cancers

REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated

Peter Voorhees named associate director of clinical research at Wake Forest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher findsCells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Never miss an issue!

Login

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response